Designer genes: Recombinant antibody fragments for biological imaging

Quarterly Journal of Nuclear Medicine

Volumn 44, Issue 3, 2000, Pages 268-283

  Wu, A M ^a   Yazaki, P J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antibodies, monoclonal; Immunoglobulins fragments; Neoplasms radionuclide imaging

Indexed keywords

COPPER 64; DIMER; FLUORINE 18; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RADIOISOTOPE; RECOMBINANT ANTIBODY; TECHNETIUM 99M;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING AFFINITY; BINDING SITE; CANCER; CANCER SCINTISCANNING; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVIEW; TARGET CELL DESTRUCTION; TRANSGENIC MOUSE;

ANIMAL; ANTIBODIES, MONOCLONAL; GENETIC ENGINEERING; IMMUNOGLOBULIN FRAGMENTS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033791994     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Radioimmunodetection in cancer identification
2. Perspectives on oncologic imaging with radiolabeled antibodies
3. A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging
4. Pharmacokinetics and biodistribution of genetically-engineered antibodies
5. Effects of genetic engineering on the pharmacokinetics of antibodies
6. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction
7. Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers
8. Phage antibodies: Filamentous phage displaying antibody variable domains
9. Human anti-self antibodies with high specificity from phage display libraries
10. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
11. Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem
12. By-passing immunization: Human antibodies from V-gene libraries displayed on phage
13. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites
14. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries
15. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency
16. Cell display library for gene cloning of variable regions of human antibodies to hepatitis B surface antigen
17. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
18. Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives
19. Antigen-specific human antibodies from mice comprising four distinct genetic modifications
20. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
21. Antibody engineering via genetic engineering of the mouse: enoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
22. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension
23. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
24. Single-chain antigen-binding proteins
25. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
26. Single-chain Fv radioimmunotargeting
27. In vivo tumor targeting of a recombinant single-chain antigen-binding protein
28. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
29. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
30. Tumor localization of anti-CEA single chain Fvs: Improved targeting by non-covalent dimers
31. A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma
32. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
33. Redesigned anti-human placental alkaline phosphatase single-chain Fv: Soluble expression, characterization, and in vivo tumour targeting
34. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
35. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts
36. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide
37. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine
38. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody
39. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex
40. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules
41. 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody
42. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2a receptor-positive tumor xenografts
43. Phage libraries for generation of clinically useful antibodies
44. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
45. Single chain antigen binding protein (sFv CC49). First human studies in colorectal carcinoma metastatic to liver
46. Construction, expression, and activity of a bivalent bispecific single-chain antibody
47. Crystallization of single-chain Fv proteins
48. 'Diabodies': Small bivalent and bispecific antibody fragments
49. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
50. In vitro and in vivo characterization of a human anti-c-erbB2 single-chain Fv isolated from a filamentous phage antibody library
51. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
52. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
53. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
54. Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv
55. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3
56. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging
57. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts
58. Crystal structure of a diabody, a bivalent antibody fragment
59. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer
60. Triabodies: Single chain Fv fragments without a linker form trivalent trimers
61. scFv multimers of the anti-neuraminidase antibody NC10: Length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies
62. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding
63. High avidity scFv multimers: Diabodies and triabodies
64. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with avidity in Escherichia coli
65. New protein engineering approaches to multivalent and bispecific antibody fragments
66. Formation of a bispecific antibody by the use of leucine zippers
67. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)
68. Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli
69. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies
70. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C(H)3) which exhibits rapid, high-level targeting of xenografts
71. Secretion of a single-gene-encoded immunoglobulin from myeloma cells
72. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins
73. Targeting of Indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: Imaging of tumors hosted in nude mice
74. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: Theoretical, experimental and clinical results
75. Pretargeting strategies for radio-immunoguided tumour localisation and therapy
76. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin
77. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics
78. A designed metal-binding protein with a novel fold
79. Immunological and structural characterization of a high affinity anti-fluorescein single-chain antibody
80. Expression of antibody genes in nonlymphoid mammalian cells
81. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
82. Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in Pichia Pastoris. The essential role of the N-domain
83. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates
84. 64Cu using a biomedical cyclotron
85. MicroPET: A high resolution PET scanner for imaging small animals
86. Numerical indicators of engineered antibody targeting: Selection of optimal tumor imaging agents
87. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies
88. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
89. Strategies to reduce renal radioactivity levels of antibody fragments
90. Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis
91. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues
92. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments
93. Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates